Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Scandic Hotels Group AB (publ) on an offering of convertible bonds and an extension of the existing credit facilities
Mandate

Vinge has advised Scandic Hotels Group AB (publ) on an offering of convertible bonds and an extension of the existing credit facilities

April 26, 2021 Banking and Finance Capital Markets and Public M&A

Vinge has advised Scandic Hotels Group AB (publ) on an offering of convertible bonds raising approximately SEK 1,609 million in gross proceeds and an extension of the existing SEK 6,650m credit facilities.

Scandic is the largest hotel company in the Nordic countries with about 58,000 rooms at approximately 280 hotels in operation and under development. Scandic is listed on Nasdaq Stockholm, Mid cap.

Vinge’s team primarily consisted of Jesper Schönbeck, Amanda Knutsson, William Kåge and Anders Sundin Lundberg (Capital markets), Louise Brorsson Salomon, Linn Adelwald, Ludvig Wettergren and Rebecka Målquist (Banking and Finance).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026